Anti Inflammatory News and Research

RSS

Tart cherry juice may help runners recover quickly and effectively from post-race pain

From gold medalists to weekend warriors, athletes at every level are in search of new ways to reduce pain and enhance post-exercise recovery. Recent research shows that drinking tart cherry juice may help runners recover more quickly and effectively from post-race pain.

26 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Sickle cell disease can be treated with resveratrol extract, according to researchers

An extract in red grape skin may be a new treatment for sickle cell disease, Medical College of Georgia researchers say.

23 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.

23 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive™ (CRx-102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia. The data demonstrated that Synavive-treated subjects maintained efficacy levels throughout the 12 month extension trial.

21 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Pfizer announces fiscal 2009 third-quarter results

Pfizer Inc. today reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3% compared with $12.0 billion in the year-ago quarter.

20 Oct 2009

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

20 Oct 2009

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

NicOx S.A. announced the presentation of detailed 26-week efficacy, safety and tolerability data from the second pivotal phase 3 study for naproxcinod (the 302 study) yesterday, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

Chrysanthemum indicum extract holds promise for treating human cancer

A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects. Recently, much attention has been devoted to the anticancer activity of Chrysanthemum indicum, especially in hepatocellular carcinoma (HCC). However, its anticancer mechanism of action is still not clear and needs further investigation.

19 Oct 2009

CeloNova BioSciences' Embozene Microspheres receives approval

CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

14 Oct 2009

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.

14 Oct 2009

Anti Inflammatory News and Research

Tart cherry juice may help runners recover quickly and effectively from post-race pain

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Sickle cell disease can be treated with resveratrol extract, according to researchers

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Celgene announces fiscal 2009 third-quarter results

NicOx reports financial results for the first nine months of 2009

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

Logical Therapeutics to present its clinical study results on LT-NS001

Positive results from KAI Pharmaceuticals' pain therapeutic program

Pfizer announces fiscal 2009 third-quarter results

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Chrysanthemum indicum extract holds promise for treating human cancer

CeloNova BioSciences' Embozene Microspheres receives approval

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News